Inclusion of a portion of the native SNCA 3′UTR reduces toxicity of human S129A SNCA on striatal-projecting dopamine neurons in rat substantia Nigra

Developmental Neurobiology

Volumn 72, Issue 6, 2012, Pages 906-917

  Khodr, Christina E ^a   Pedapati, Jyothi ^a   Han, Ye ^a   Bohn, Martha C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Gene therapy; MicroRNA; Neurodegeneration; Phosphorylation; Retrograde labeling

Indexed keywords

ALPHA SYNUCLEIN; DNA; FLUOROGOLD; MICRORNA; PARVOVIRUS VECTOR; RNA;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INCLUSION; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; ELECTRON MICROSCOPY; GENE EXPRESSION; GENE THERAPY; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LEWY BODY; MALE; NEUROLOGIC DISEASE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEREOTAXIC SURGERY; SUBSTANTIA NIGRA; TRANSGENE;

3' UNTRANSLATED REGIONS; ALPHA-SYNUCLEIN; ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; GENE THERAPY; MALE; NERVE DEGENERATION; NEURAL PATHWAYS; PARKINSON DISEASE; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA;

EID: 84860904863     PISSN: 19328451     EISSN: 10974695     Source Type: Journal    
DOI: 10.1002/dneu.20989     Document Type: Article

References (40)

1. Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, et al. 2006. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281: 29739-29752.
2. Auluck PK, Caraveo G, Lindquist S. 2010. alpha-Synuclein: Membrane interactions and toxicity in Parkinson's disease. Annu Rev Cell Dev Biol 26: 211-233.
3. Azeredo da Silveira S, Schneider BL, Cifuentes-Diaz C, Sage D, Abbas-Terki T, Iwatsubo T, Unser M, Aebischer P. 2009. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. Hum Mol Genet 18: 872-887.
4. Baptista MJ, O'Farrell C, Daya S, Ahmad R, Miller DW, Hardy J, Farrer MJ, et al. 2003. Co-ordinate transcriptional regulation of dopamine synthesis genes by alpha-synuclein in human neuroblastoma cell lines. J Neurochem 85: 957-968.
5. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, et al. 2004. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364: 1167-1169.
6. Chen L, Feany MB. 2005. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 8: 657-663.
7. Chen L, Periquet M, Wang X, Negro A, McLean PJ, Hyman BT, Feany MB. 2009. Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J Clin Invest 119: 3257-3265.
8. Doxakis E. 2010. Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153. J Biol Chem 285: 12726-12734.
9. Fuchs J, Tichopad A, Golub Y, Munz M, Schweitzer KJ, Wolf B, Berg D, et al. 2008. Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J 22: 1327-1334.
10. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, et al. 2002. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4: 160-164.
11. Gorbatyuk OS, Li S, Sullivan LF, Chen W, Kondrikova G, Manfredsson FP, Mandel RJ, et al. 2008. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc Natl Acad Sci USA 105: 763-768.
12. Jowaed A, Schmitt I, Kaut O, Wullner U. 2010. Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains. J Neurosci 30: 6355-6359.
13. Junn E, Lee KW, Jeong BS, Chan TW, Im JY, Mouradian MM. 2009. Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc Natl Acad Sci USA 106: 13052-13057.
14. Khodr CE, Sapru MK, Pedapati J, Han Y, West NC, Kells AP, Bankiewicz KS, et al. 2011. An alpha-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons. Brain Res 1395: 94-107.
15. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, et al. 1998. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18: 106-108.
16. Lee VM, Trojanowski JQ. 2006. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: New targets for drug discovery. Neuron 52: 33-38.
17. Linnertz C, Saucier L, Ge D, Cronin KD, Burke JR, Browndyke JN, Hulette CM, et al. 2009. Genetic regulation of alpha-synuclein mRNA expression in various human brain tissues. PLoS One 4: e7480.
18. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
19. Maraganore DM, de Andrade M, Elbaz A, Farrer MJ, Ioannidis JP, Kruger R, Rocca WA, et al. 2006. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 296: 661-670.
20. Matsumoto L, Takuma H, Tamaoka A, Kurisaki H, Date H, Tsuji S, Iwata A. 2010. CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease. PLoS One 5: e15522.
21. McCarthy JJ, Linnertz C, Saucier L, Burke JR, Hulette CM, Welsh-Bohmer KA, Chiba-Falek O. 2011. The effect of SNCA 3′ region on the levels of SNCA-112 splicing variant. Neurogenetics 12: 59-64.
22. McCormack AL, Di Monte DA. 2009. Enhanced alpha-synuclein expression in human neurodegenerative diseases: Pathogenetic and therapeutic implications. Curr Protein Pept Sci 10: 476-482.
23. McFarland NR, Fan Z, Xu K, Schwarzschild MA, Feany MB, Hyman BT, McLean PJ. 2009. alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. J Neuropathol Exp Neurol 68: 515-524.
24. Mueller JC, Fuchs J, Hofer A, Zimprich A, Lichtner P, Illig T, Berg D, et al. 2005. Multiple regions of alpha-synuclein are associated with Parkinson's disease. Ann Neurol 57: 535-541.
25. Myhre R, Toft M, Kachergus J, Hulihan MM, Aasly JO, Klungland H, Farrer MJ. 2008. Multiple alpha-synuclein gene polymorphisms are associated with Parkinson's disease in a Norwegian population. Acta Neurol Scand 118: 320-327.
26. Oueslati A, Fournier M, Lashuel HA. 2010. Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: Implications for Parkinson's disease pathogenesis and therapies. Prog Brain Res 183: 115-145.
27. Paleologou KE, Oueslati A, Shakked G, Rospigliosi CC, Kim HY, Lamberto GR, Fernandez CO, et al. 2010. Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J Neurosci 30: 3184-3198.
28. Perez RG, Waymire JC, Lin E, Liu JJ, Guo F, Zigmond MJ. 2002. A role for alpha-synuclein in the regulation of dopamine biosynthesis. J Neurosci 22: 3090-3099.
29. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, et al. 1997. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047.
30. Rogers JT, Mikkilineni S, Cantuti-Castelvetri I, Smith DH, Huang X, Bandyopadhyay S, Cahill CM, et al. 2011. The alpha-synuclein 5'untranslated region targeted translation blockers: Anti-alpha synuclein efficacy of cardiac glycosides and Posiphen. J Neural Transm 118: 493-507.
31. Ross OA, Gosal D, Stone JT, Lincoln SJ, Heckman MG, Irvine GB, Johnston JA, et al. 2007. Familial genes in sporadic disease: common variants of alpha-synuclein gene associate with Parkinson's disease. Mech Age Dev 128: 378-382.
32. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, et al. 2003. alpha-Synuclein locus triplication causes Parkinson's disease. Science 302: 841.
33. Sotiriou S, Gibney G, Baxevanis AD, Nussbaum RL. 2009. A single nucleotide polymorphism in the 3′UTR of the SNCA gene encoding alpha-synuclein is a new potential susceptibility locus for Parkinson disease. Neurosci Lett 461: 196-201.
34. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. 1998. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci USA 95: 6469-6473.
35. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. 1997. Alpha-synuclein in Lewy bodies. Nature 388: 839-840.
36. Winkler S, Hagenah J, Lincoln S, Heckman M, Haugarvoll K, Lohmann-Hedrich K, Kostic V, et al. 2007. alpha-Synuclein and Parkinson disease susceptibility. Neurology 69: 1745-1750.
37. Wood-Kaczmar A, Gandhi S, Wood NW. 2006. Understanding the molecular causes of Parkinson's disease. Trends Mol Med 12: 521-528.
38. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, et al. 2004. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55: 164-173.
39. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L, Trono D. 1998. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72: 9873-9880.
40. Zufferey R, Trono D. 2002. Production of High-Titer Lentiviral Vectors. New York: Wiley. pp 1-12.